Hydrogel Delivery Device for the In Vitro and In Vivo Sustained Release of Active rhGALNS Enzyme

Hydrogel Delivery Device for the In Vitro and In Vivo Sustained Release of Active rhGALNS Enzyme

Morquio A disease is a genetic disorder resulting in N-acetylgalactosamine-6-sulfate sulfatase (GALNS) deficiency, and patients are currently treated with enzyme replacement therapy via weekly intravenous enzyme infusions. A means of sustained enzyme delivery could improve patient quality of life by...

Full description

Bibliographic Details
Main Authors: Michael Flanagan, Qi Gan, Saahil Sheth, Rachel Schafer, Samuel Ruesing, Linda E. Winter, Karoly Toth, Silviya P. Zustiak, Adriana M. Montaño
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:Pharmaceuticals
Subjects:
polyethylene glycol hydrogel
drug delivery
sustained release
Morquio A
GALNS
Online Access:https://www.mdpi.com/1424-8247/16/7/931

Internet

https://www.mdpi.com/1424-8247/16/7/931

Similar Items